Search
Research
Clinical experience with SUBA-itraconazole at a tertiary paediatric hospitalItraconazole remains a first-line antifungal agent for certain fungal infections in children, including allergic bronchopulmonary aspergillosis (ABPA) and sporotrichosis, but poor attainment of therapeutic drug levels is frequently observed with available oral formulations. A formulation of 'SUper BioAvailability itraconazole' (SUBA-itraconazole; Lozanoc®) has been developed, with adult studies demonstrating rapid and reliable attainment of therapeutic levels, yet paediatric data are lacking.
Research
Introduction to the updated Australasian consensus guidelines for the management of invasive fungal disease and use of antifungal agents in the haematology/oncology setting, 2021This article introduces the fourth update of the Australian and New Zealand consensus guidelines for the management of invasive fungal disease and use of antifungal agents in the haematology/oncology setting. These guidelines are comprised of nine articles as presented in this special issue of the Internal Medicine Journal. This introductory chapter outlines the rationale for the current update and the steps taken to ensure implementability in local settings.
Research
Consensus guidelines for the diagnosis and management of invasive aspergillosis, 2021Invasive aspergillosis (IA) in haematology/oncology patients presents as primary infection or breakthrough infection, which can become refractory to antifungal treatment and has a high associated mortality. Other emerging patient risk groups include patients in the intensive care setting with severe respiratory viral infections, including COVID-19.
Research
Investigation of group A Streptococcus immune responses in an endemic setting, with a particular focus on J8We analysed the stimulation of J8 antibodies in response to infection, and the role of existing J8 antibodies in protection against subsequent infection
Research
Treatment, prevention and public health management of impetigo, scabies, crusted scabies and fungal skin infections in endemic populations: a systematic reviewSystematic review of the treatment, prevention and public health control of skin infections in resource-limited settings where skin infections are endemic
Research
Perinatal risk factors associated with skin infection hospitalisation in Western Australian Aboriginal and Non-Aboriginal childrenWe have quantified the relative influence of perinatal risk factors associated with skin infection hospitalisations in WA children
Research
The global epidemiology of impetigo: A systematic review of the population prevalence of impetigo and pyodermaWe conducted a comprehensive, systematic review of the global childhood population prevalence of impetigo and the broader condition pyoderma.
News & Events
National guideline to tackle record rates of skin infectionResearchers have developed the first National Healthy Skin Guideline to address record rates of skin infections in Australia’s Indigenous communities.
News & Events
Major grant empowers community voices to drive reduction in skin infectionsAboriginal community members throughout the Kimberley will take a lead role in driving healthy skin messages within their own communities thanks to a major funding boost to The Kids Research Institute Australia’s SToP Trial.
Research
Culturally supported health promotion to See, Treat, Prevent (SToP) skin infections in Aboriginal children living in the Kimberley region of Western Australia: a qualitative analysisWhile there are many skin infections, reducing the burden of scabies and impetigo for remote living Aboriginal people, particularly children remains challenging. Aboriginal children living in remote communities have experienced the highest reported rate of impetigo in the world and are 15 times more likely to be admitted to hospital with a skin infection compared to non-Aboriginal children.